August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Sara Tolaney Leads A012103 Trial to Compare Pembrolizumab to Observation in TNBC
Aug 29, 2025, 15:00

Sara Tolaney Leads A012103 Trial to Compare Pembrolizumab to Observation in TNBC

Alliance for Clinical Trials in Oncology shared a post on X:

Sara Tolaney leads Alliance for Clinical Trials in Oncology A012103 to compare the effect of pembrolizumab to observation in pts with triple-negative breast cancer who had a pathologic complete response after chemotherapy plus pembrolizumab.”

Learn more here.

Sarah Sammons, Sara Tolaney

Sarah Sammons, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post by Alliance for Clinical Trials in Oncology on X, adding:

”We don’t know if TNBC patients who have pCR after Keynote 522 really benefit from 9 more cycles of pembro.

This trial will answer.”

More posts featuring Sarah Sammons.